In this white paper, we discuss how cell engagers could overcome challenges presented by current CAR-T therapies with improved simplicity in manufacturing and off-the-shelf treatment capabilities. In addition, we discuss the new LUMICKS high throughput service platform’s ability to measure hundreds of cell engagers for rapid and cost-effective ranking and selection of the most potent cell engagers.
Learning objectives:
- The next generation of Cell Engagers(CEs) for cancer treatment will need to show greater efficacy and reduce time-to-market to be included among the treatment options for solid and liquid tumor indications.
- Cell Avidity is a novel biomarker for antitumor efficacy, report to be up to 50% more predictive of in vivo outcomes compared to traditional in vitro techniques.
- Cell Avidity analysis can be performed at high throughput, enabling the screening of hundreds of Cell Engagers for rapid and cost-effective selection of lead Cell Engager candidates for in vivo assessment and clinical trials.
- Faster and more reliable route to a successful Investigational New Drug (IND) filing and further clinical development
